We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$43.9B
AUM Growth
+$2.87B
(+7%)
Cap. Flow
-$890M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
13.25%
Holding
2,343
New
170
Increased
997
Reduced
1,015
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$111M |
| 2 |
Verizon
VZ
|
+$103M |
| 3 |
AT&T
T
|
+$103M |
| 4 |
Kroger
KR
|
+$97.1M |
| 5 |
3M
MMM
|
+$92.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$138M |
| 2 |
Tesla
TSLA
|
+$110M |
| 3 |
JPMorgan Chase
JPM
|
+$103M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$89.4M |
| 5 |
Apple
AAPL
|
+$85.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 16.25% |
| 3 | Financials | 11.85% |
| 4 | Industrials | 11.44% |
| 5 | Consumer Discretionary | 10.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Mastercard
MA
$493B
| $235M | 0.53% |
680,175
-5,783
| -0.8% | -$1.9M |
|
27
LyondellBasell Industries
LYB
$19.2B
| $233M | 0.53% |
2,818,225
-706,331
| -20% | -$57.9M |
|
|
28
Verizon
VZ
$196B
| $229M | 0.52% |
5,811,271
+2,744,166
| +89% | +$103M |
|
29
AbbVie
ABBV
$435B
| $229M | 0.52% |
1,421,807
-36,141
| -2% | -$5.54M |
|
|
30
Kroger
KR
$34.8B
| $226M | 0.51% |
5,066,253
+2,114,418
| +72% | +$97.1M |
|
|
31
Regeneron Pharmaceuticals
REGN
$80.8B
| $221M | 0.5% |
309,155
-121,146
| -28% | -$89.4M |
|
|
32
3M
MMM
$94.3B
| $221M | 0.5% |
2,213,589
+910,906
| +70% | +$92.9M |
|
33
Arrow Electronics
ARW
$10.4B
| $217M | 0.49% |
2,080,855
-170,282
| -8% | -$17.6M |
|
34
Broadcom
AVGO
$2.04T
| $208M | 0.47% |
3,763,160
+563,230
| +18% | +$28.2M |
|
35
American International
AIG
$41.3B
| $205M | 0.47% |
3,237,547
-475,300
| -13% | -$27.7M |
|
36
Abbott
ABT
$187B
| $198M | 0.45% |
1,810,977
+139,394
| +8% | +$14.4M |
|
37
Cigna
CI
$74.6B
| $196M | 0.45% |
592,977
+227,975
| +62% | +$72.1M |
|
38
Texas Instruments
TXN
$261B
| $191M | 0.43% |
1,169,856
-123,053
| -10% | -$20.5M |
|
39
Walmart Inc
WMT
$890B
| $188M | 0.43% |
3,978,576
-345,183
| -8% | -$16.4M |
|
40
Intel
INTC
$513B
| $183M | 0.42% |
7,041,941
-450,502
| -6% | -$12.5M |
|
41
Danaher
DHR
$144B
| $173M | 0.39% |
735,873
+144,651
| +24% | +$33.5M |
|
42
Marathon Petroleum
MPC
$83.7B
| $171M | 0.39% |
1,473,828
+174,979
| +13% | +$19.9M |
|
43
Wells Fargo
WFC
$264B
| $169M | 0.39% |
4,102,044
-118,129
| -3% | -$5.23M |
|
44
Vertex Pharmaceuticals
VRTX
$126B
| $169M | 0.38% |
587,594
+93,063
| +19% | +$28.4M |
|
45
Expedia Group
EXPE
$37.3B
| $168M | 0.38% |
1,944,108
+487,027
| +33% | +$46.1M |
|
46
Valero Energy
VLO
$85.9B
| $166M | 0.38% |
1,306,636
-151,574
| -10% | -$19M |
|
47
CF Industries
CF
$17.3B
| $165M | 0.38% |
1,949,757
+293,137
| +18% | +$29.8M |
|
48
EOG Resources
EOG
$70.7B
| $161M | 0.37% |
1,254,333
-484,072
| -28% | -$64.4M |
|
49
Bristol-Myers Squibb
BMY
$132B
| $160M | 0.36% |
2,230,635
+598,538
| +37% | +$45.1M |
|
50
Amgen
AMGN
$222B
| $159M | 0.36% |
606,517
-18,991
| -3% | -$5.09M |
|
Similar funds
VGA
AQR Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, AQR Capital Management held 2,343 positions worth $43.9B, up 7% from $41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
AQR Capital Management's Q4 2022 filing shows 170 new, 997 increased, 1,015 reduced and 150 closed positions. Its largest new stake was Generac Holdings: 310,080 shares worth $30.5M. The largest sale was Gilead Sciences, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q4 2022 buy was Generac Holdings: 310,080 shares worth $30.5M.
- AQR Capital Management added most to Humana in Q4 2022, an estimated $111M increase.
- AQR Capital Management's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $138M.
- AQR Capital Management fully exited Abiomed Inc in Q4 2022, selling an estimated $22.4M.
- AQR Capital Management's ten largest holdings make up 13% of its $43.9B portfolio in Q4 2022.
- AQR Capital Management opened 170 new positions and closed 150 in Q4 2022.
- AQR Capital Management's portfolio value rose 7% quarter-over-quarter to $43.9B.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.